中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 11
Nov.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(11): 2141-2144

Hotspots and challenges in blocking the mother-to-child transmission of hepatitis B virus

DOI: 10.12449/JCH241102

  • Department of Infectious Diseases，Nanfang Hospital，Southern Medical University；State Key Laboratory of Organ Failure Research；Key Laboratory of Infectious Diseases Research in South China，Ministry of Education；Guangdong Provincial Key Laboratory of Viral Hepatitis Research；Guangdong Provincial Clinical Research Center for Viral Hepatitis；Guangdong Institute of Hepatology，Guangzhou 510515，China

Research funding:

Science and Technology Projects in Guangzhou (2023A04J2299)

More Information
  • Corresponding author: YIN Xueru， evonneyin@163.com （ORCID： 0000-0001-9469-9366）
  • Received Date: 2024-09-03
  • Accepted Date: 2024-10-04
  • Published Date: 2024-11-25
    Abstract
  • Chronic hepatitis B virus （HBV） infection remains a major public health challenge in China， affecting over 70 million people and posing great challenges to the prevention and control of the disease. At present， both the government and sectors of the society are making efforts to achieve the goal of eliminating viral hepatitis as a public health threat by 2030. Mother-to-child transmission is the main route of transmission of HBV， and therefore， blocking the mother-to-child transmission of HBV is the key link in eliminating viral hepatitis. At present， several critical issues still remain unresolved， including the long-term safety of tenofovir alafenamide fumarate during pregnancy， the safety of antiviral therapy in early pregnancy， the effectiveness of immunoglobulin-free strategy， and the risk of HBV transmission through germ cells. Addressing these challenges is important for promoting the blocking of the mother-to-child transmission of HBV and accelerating the progress toward the 2030 goals.

     

    • FullText(HTML)
  • loading
    • References(31)
  • [1]
    World Health Organization. Global health sector strategy on viral hepatitis 2016-2021[R]. Geneva: World Health Organization, 2016.
    [2]
    Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study[J]. Lancet Gastroenterol Hepatol, 2023, 8( 10): 879- 907. DOI: 10.1016/S2468-1253(23)00197-8.
    [3]
    LIANG XF, BI SL, YANG WZ, et al. Epidemiological serosurvey of hepatitis B in China: Declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27( 47): 6550- 6557. DOI: 10.1016/j.vaccine.2009.08.048.
    [4]
    Infectious Diseases Physicians Branch, Chinese Medical Doctor Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Chinese practice guideline for the prevention and treatment of mother-to-child transmission of hepatitis B virus(version 2024)[J]. J Clin Hepatol, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809.

    中国医师协会感染科医师分会, 中华医学会感染病学分会. 中国乙型肝炎病毒母婴传播防治指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 8): 1557- 1566. DOI: 10.12449/JCH240809.
    [5]
    European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67( 2): 370- 398. DOI: 10.1016/j.jhep.2017.03.021.
    [6]
    TERRAULT NA, LOK ASF, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67( 4): 1560- 1599. DOI: 10.1002/hep.29800.
    [7]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [8]
    PAN SF, ZHANG Y, ZENG YF, et al. Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study[J]. Immun Inflamm Dis, 2024, 12( 2): e1204. DOI: 10.1002/iid3.1204.
    [9]
    ZENG QL, YU ZJ, JI F, et al. Tenofovir alafenamide to prevent perinatal hepatitis B transmission: A multicenter, prospective, observational study[J]. Clin Infect Dis, 2021, 73( 9): e3324- e3332. DOI: 10.1093/cid/ciaa1939.
    [10]
    DING Y, CAO LH, ZHU LY, et al. Efficacy and safety of tenofovir alafenamide fumarate for preventing mother-to-child transmission of hepatitis B virus: A national cohort study[J]. Aliment Pharmacol Ther, 2020, 52( 8): 1377- 1386. DOI: 10.1111/apt.16043.
    [11]
    ZENG QL, ZHANG HX, ZHANG JY, et al. Tenofovir alafenamide for pregnant Chinese women with active chronic hepatitis B: A multicenter prospective study[J]. Clin Gastroenterol Hepatol, 2022, 20( 12): 2826- 2837. e 9. DOI: 10.1016/j.cgh.2021.12.012.
    [12]
    PREBOTH M. The antiretroviral pregnancy registry interim report[J]. Am Fam Physician, 2000, 61( 7): 2265.
    [13]
    CHEN RC, ZOU J, LONG LY, et al. Safety and efficacy of tenofovir alafenamide fumarate in early-middle pregnancy for mothers with chronic hepatitis B[J]. Front Med(Lausanne), 2022, 8: 796901. DOI: 10.3389/fmed.2021.796901.
    [14]
    YIN XR, HAN GR, ZHANG H, et al. A real-world prospective study of mother-to-child transmission of HBV in China using a mobile health application(shield 01)[J]. J Clin Transl Hepatol, 2020, 8( 1): 1- 8. DOI: 10.14218/JCTH.2019.00057.
    [15]
    YIN XR, WANG W, CHEN H, et al. Real-world implementation of a multilevel interventions program to prevent mother-to-child transmission of HBV in China[J]. Nat Med, 2024, 30( 2): 455- 462. DOI: 10.1038/s41591-023-02782-x.
    [16]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Chin J Clin Infect Dis, 2022, 15( 6): 401- 427. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.001.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15( 6): 401- 427. DOI: 10.3760/cma.j.issn.1674-2397.2022.06.001.
    [17]
    World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[EB/OL].( 2024-03-29)[ 2024-09-21]. https://www.who.int/publications/i/item/9789240090903. https://www.who.int/publications/i/item/9789240090903
    [18]
    PAN CQ, DAI EH, YANG CL, et al. Tenofovir-df therapy prevents hepatitis B vertical transmission in highly viremic mothers without hbv immunoglobulin for infants[EB/OL].( 2022-10-21). https://aasldpubs.onlinelibrary.wiley.com/doi/epdf/10.1002/hep.32697. DOI: 10.1002/hep.32697
    [19]
    SEGERAL O, DIM B, DURIER C, et al. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia(TA-PROHM): A single-arm, multicentre, phase 4 trial[J]. Lancet Infect Dis, 2022, 22( 8): 1181- 1190. DOI: 10.1016/S1473-3099(22)00206-7.
    [20]
    SMITH K, SPADAFORA C. Sperm-mediated gene transfer: Applications and implications[J]. Bioessays, 2005, 27( 5): 551- 562. DOI: 10.1002/bies.20211.
    [21]
    SPADAFORA C. Sperm cells and foreign DNA: A controversial relation[J]. Bioessays, 1998, 20( 11): 955- 964. DOI:10.1002/(SICI)1521-1878(199811)20:11<955:AID-BIES11>3.0.CO;2-8.
    [22]
    SCIAMANNA I, VITULLO P, CURATOLO A, et al. Retrotransposons, reverse transcriptase and the genesis of new genetic information[J]. Gene, 2009, 448( 2): 180- 186. DOI: 10.1016/j.gene.2009.07.011.
    [23]
    PITTOGGI C, BERALDI R, SCIAMANNA I, et al. Generation of biologically active retro-genes upon interaction of mouse spermatozoa with exogenous DNA[J]. Mol Reprod Dev, 2006, 73( 10): 1239- 1246. DOI: 10.1002/mrd.20550.
    [24]
    BA ALI, HUANG TH, XIE QD. Detection and expression of hepatitis B virus X gene in one and two-cell embryos from golden Hamster oocytes in vitro fertilized with human spermatozoa carrying HBV DNA[J]. Mol Reprod Dev, 2005, 70( 1): 30- 36. DOI: 10.1002/mrd.20185.
    [25]
    ZHANG LY, FANG ZX, ZHENG Z, et al. Prelminary research on the paternal-fetal transmission of hepatitis b virus[J]. Chin J Infect Dis, 1994, 12( 4): 199- 201.

    张丽云, 方之勋, 郑兆, 等. 乙型肝炎病毒父婴传播途径的初步研究[J]. 中华传染病杂志, 1994, 12( 4): 199- 201.
    [26]
    YE F, YUE YF, LI SH, et al. Presence of HBsAg, HBcAg, and HBVDNA in ovary and ovum of the patients with chronic hepatitis B virus infection[J]. Am J Obstet Gynecol, 2006, 194( 2): 387- 392. DOI: 10.1016/j.ajog.2005.07.011.
    [27]
    NIE R, JIN L, ZHANG HW, et al. Presence of hepatitis B virus in oocytes and embryos: A risk of hepatitis B virus transmission during in vitro fertilization[J]. Fertil Steril, 2011, 95( 5): 1667- 1671. DOI: 10.1016/j.fertnstert.2010.12.043.
    [28]
    KONG Y, LIU Y, LIU XJ, et al. Relationship between the mechanism of hepatitis B virus father-infant transmission and pregnancy outcome[J]. Arch Gynecol Obstet, 2017, 295( 1): 253- 257. DOI: 10.1007/s00404-016-4231-6.
    [29]
    HUANG JM, HUANG TH, QIU HY, et al. Studies on the integration of hepatitis B virus DNA sequence in human sperm chromosomes[J]. Asian J Androl, 2002, 4( 3): 209- 212.
    [30]
    YI W, LI MH, SUN FF, et al. Impact of in vitro fertilization-embryo transfer on mother-to-infant transmission in women with chronic HBV infection[J]. Liver Int, 2022, 42( 10): 2167- 2174. DOI: 10.1111/liv.15349.
    [31]
    NIE R, WANG MY, LIAO TT, et al. Assisted conception does not increase the risk for mother-to-child transmission of hepatitis B virus, compared with natural conception: A prospective cohort study[J]. Fertil Steril, 2019, 111( 2): 348- 356. DOI: 10.1016/j.fertnstert.2018.10.021.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (192) PDF downloads(73) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return